Jump to content

Spark Therapeutics: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Clean up duplicate template arguments using findargdups: repairing duplicate |parent =;
Line 64: Line 64:
[[Category:Health care companies based in Pennsylvania]]
[[Category:Health care companies based in Pennsylvania]]
[[Category:Virotherapy]]
[[Category:Virotherapy]]
[[Category:Companies listed on NASDAQ]]
[[Category:Companies formerly listed on NASDAQ]]
[[Category:2015 initial public offerings]]
[[Category:2015 initial public offerings]]
[[Category:Announced mergers and acquisitions]]
[[Category:2019 mergers and acquisitions]]
[[Category:Hoffmann-La Roche]]

[[Category:American subsidiaries of foreign companies]]


{{US-company-stub}}
{{US-company-stub}}

Revision as of 06:54, 19 December 2019

Spark Therapeutics
Company typeSubsidiary
IndustryBiotechnology, Pharmaceutical
Founded2013; 11 years ago (2013) in Philadelphia, Pennsylvania, United States of America
FoundersJeffrey Marrazzo, Katherine High
Headquarters
Philadelphia
,
United States of America
ParentHoffmann-La Roche
Websitesparktx.com

Spark Therapeutics is a startup pharmaceutical company that develops gene therapies.[1][2][3] It was founded in 2013 by Katherine High and Jeffrey Marrazzo in an effort to commercially develop treatments against haemophilia that High was working on at Children's Hospital of Philadelphia.[4]

In February 2019, Roche announced it would acquire the company for $4.3 billion ($114.50 per share).[5][6] In December 2019, the transaction was completed.[7]

Products and pipeline

Voretigene neparvovec

Main article: Voretigene neparvovec

Voretigene neparvovec, marketed under the tradename Luxturna, is a gene therapy approved by the Food and Drug Administration for treatment of Leber's congenital amaurosis, a rare genetic eye disease.[8]

Fidanacogene elaparvovec

Fidanacogene elaparvovec, previously known by its study ID number SPK-9001,[9] is an experimental drug under investigation for treatment of hemophilia B. Spark partnered with pharmaceutical giant Pfizer to develop fidanacogene elaparvovec.[2] Fidanacogene elaparvovec is an adeno-associated viral vector which is designed to transfer a working copy of the Factor IX gene into the livers of patients who carry non-functioning copies.[10] In July 2018, Pfizer said fidanacogene elaparvovec was entering late stage clinical trials.[11]

SPK-8011

SPK-8011 is an experimental drug under investigation for treatment of hemophilia A. It is entering phase III clinical trials in the United States. The therapy transfers a working copy of the Factor VIII gene into patients who lack one. In Phase II clinical trials, 2 of 7 patients receiving the highest dose of the drug suffered immune responses. One patient had to be hospitalized. The reactions against the treatment were seen as a set back, though Spark suggested that the responses could be controlled with steroids, and promised to move forward with Phase III testing.[12][13]

SPK-7001

SPK-7001 is an experimental drug under investigation for treatment of choroideremia, a genetic disorder that causes blindness.[14]

SPK-3006

SPK-3006 is an experimental drug under investigation for treatment of Pompe disease, a genetic disorder that leads to failure to correctly metabolize glycogen.[14]

SPK-1001

SPK-1001 is an experimental drug under investigation for treatment of Batten disease, a fatal genetic, nervous system disorder.[14]

References

  1. ^ "Spark Therapeutics reports 3Q loss". Associated Press. 7 November 2017. Retrieved 16 November 2017.
  2. ^ a b George, John (7 November 2017). "Spark, Pfizer amend agreement for experimental hemophilia gene therapy". Philadelphia Business Journal. Retrieved 16 November 2017.
  3. ^ Marchione, Marilynn (10 October 2017). "A gene therapy that could cure blindness is on the brink of getting approved". Business Insider. Retrieved 16 November 2017.
  4. ^ Crow, David (19 October 2017). "Gene therapy helped these children see. Can it transform medicine?". Financial Times. Retrieved 16 November 2017.
  5. ^ "Roche 'steps up' for gene therapy with $4.3 billion Spark bet". 25 February 2019 – via uk.reuters.com.
  6. ^ Grover, Natalie (25 October 2019). "UPDATED: FTC staff signs off on Roche $4.3B deal for Spark — report". EndpointNews. {{cite web}}: no-break space character in |title= at position 61 (help)
  7. ^ "Roche completes $4.3B purchase of Philadelphia gene therapy pioneer Spark Therapeutics". 17 December 2019.
  8. ^ "FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss". FDA. 19 Dec 2017. Retrieved 20 Dec 2017.
  9. ^ "Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy" (Press release). Pfizer. 16 July 2018. Retrieved 2018-07-18.
  10. ^ Lindsey, George (1 December 2016). "Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression". Blood. 128 (22): 3. doi:10.1182/blood.V128.22.3.3. Retrieved 16 November 2017.
  11. ^ George, John (16 July 2018). "Pfizer begins late-stage testing of Spark's hemophilia B gene therapy". Philadelphia Business Journal. Retrieved 18 July 2018.
  12. ^ Garde, Damian (7 August 2018). "Spark's gene therapy data answer some burning questions — and raise a few more". Stat. Retrieved 7 August 2018.
  13. ^ Tirrell, Meg (7 August 2018). "Spark Therapeutics shares lose a third of their value as hemophilia gene therapy trial disappoints investors". CNBC. Retrieved 7 August 2018.
  14. ^ a b c Morrison, Chris (5 March 2019). "Spark's meteoric rise from hospital-funded spinout to $4.8 billion deal". Nature Biotechnology. Retrieved 8 February 2019.
Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Spark_Therapeutics&oldid=931501181"